Troy J Kemp1, Felipe A Castro2, Yu-Tang Gao3, Allan Hildesheim4, Leticia Nogueira5, Bing-Sheng Wang6, Lu Sun7, Gloriana Shelton8, Ruth M Pfeiffer9, Ann W Hsing10, Ligia A Pinto11, Jill Koshiol12. 1. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. Electronic address: kemptj@mail.nih.gov. 2. Infections and Immunoepidemiology Branch, DCEG, NCI, NIH, Bethesda, MD, USA. Electronic address: felipe.castro@nih.gov. 3. Department of Epidemiology, Shanghai Cancer Institute, Shanghai Cancer Institute, Shanghai, China. Electronic address: ytgao@vip.sina.com. 4. Infections and Immunoepidemiology Branch, DCEG, NCI, NIH, Bethesda, MD, USA. Electronic address: hildesha@exchange.nih.gov. 5. Infections and Immunoepidemiology Branch, DCEG, NCI, NIH, Bethesda, MD, USA. Electronic address: leticia.nogueira@nih.gov. 6. Department of General Surgery, Zhongshan Hospital, School of Medicine, Fudan University, Shanghai, China. Electronic address: wang.bingsheng@zs-hospital.sh.cn. 7. Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China. Electronic address: sunlush@126.com. 8. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. Electronic address: Gloriana.Shelton@nih.gov. 9. Biostatistics Branch, DCEG, NCI, NIH, Bethesda, MD, USA. Electronic address: pfeiffer@mail.nih.gov. 10. Cancer Prevention Institute of California, Fremont, CA, USA; Stanford Cancer Institute, Palo Alto, CA, USA; Department of Health Research and Policy, School of Medicine, Stanford University, Palo Alto, CA, USA. Electronic address: Ann.Hsing@cpic.org. 11. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. Electronic address: pintol@mail.nih.gov. 12. Infections and Immunoepidemiology Branch, DCEG, NCI, NIH, Bethesda, MD, USA. Electronic address: koshiolj@mail.nih.gov.
Abstract
BACKGROUND: Gallbladder disease is highly related to inflammation, but the inflammatory processes are not well understood. Bile provides a direct substrate in assessing the local inflammatory response that develops in the gallbladder. To assess the reproducibility of measuring inflammatory markers in bile, we designed a methods study of 69 multiplexed immune-related markers measured in bile obtained from gallstone patients. METHODS: To evaluate assay performance, a total of 18 bile samples were tested twice within the same plate for each analyte, and the 18 bile samples were tested on two different days for each analyte. We used the following performance parameters: detectability, coefficient of variation (CV), intraclass correlation coefficient (ICC), and percent agreement (concordance among replicate measures above and below detection limit). Furthermore, we examined the association of analyte levels with gallstone characteristics such as type, numbers, and size. RESULTS: All but 3 analytes (Stem Cell Factor, SCF; Thrombopoietin, TPO; sIL-1RI) were detectable in bile. 52 of 69 (75.4%) analytes had detectable levels for at least 50% of the subjects tested. The within-plate CVs were ⩽25% for 53 of 66 (80.3%) detectable analytes, and across-plate CVs were ⩽25% for 32 of 66 (48.5%) detectable analytes. Moreover, 64 of 66 (97.0%) analytes had ICC values of at least 0.8. Lastly, the percent agreement was high between replicates for all of the analytes (median; within plate, 97.2%; across plate, 97.2%). In exploratory analyses, we assessed analyte levels by gallstone characteristics and found that levels for several analytes decreased with increasing size of the largest gallstone per patient. CONCLUSIONS: Our data suggest that multiplex assays can be used to reliably measure cytokines and chemokines in bile. In addition, gallstone size was inversely related to the levels of select analytes, which may aid in identifying critical pathways and mechanisms associated with the pathogenesis of gallbladder diseases.
BACKGROUND:Gallbladder disease is highly related to inflammation, but the inflammatory processes are not well understood. Bile provides a direct substrate in assessing the local inflammatory response that develops in the gallbladder. To assess the reproducibility of measuring inflammatory markers in bile, we designed a methods study of 69 multiplexed immune-related markers measured in bile obtained from gallstonepatients. METHODS: To evaluate assay performance, a total of 18 bile samples were tested twice within the same plate for each analyte, and the 18 bile samples were tested on two different days for each analyte. We used the following performance parameters: detectability, coefficient of variation (CV), intraclass correlation coefficient (ICC), and percent agreement (concordance among replicate measures above and below detection limit). Furthermore, we examined the association of analyte levels with gallstone characteristics such as type, numbers, and size. RESULTS: All but 3 analytes (Stem Cell Factor, SCF; Thrombopoietin, TPO; sIL-1RI) were detectable in bile. 52 of 69 (75.4%) analytes had detectable levels for at least 50% of the subjects tested. The within-plate CVs were ⩽25% for 53 of 66 (80.3%) detectable analytes, and across-plate CVs were ⩽25% for 32 of 66 (48.5%) detectable analytes. Moreover, 64 of 66 (97.0%) analytes had ICC values of at least 0.8. Lastly, the percent agreement was high between replicates for all of the analytes (median; within plate, 97.2%; across plate, 97.2%). In exploratory analyses, we assessed analyte levels by gallstone characteristics and found that levels for several analytes decreased with increasing size of the largest gallstone per patient. CONCLUSIONS: Our data suggest that multiplex assays can be used to reliably measure cytokines and chemokines in bile. In addition, gallstone size was inversely related to the levels of select analytes, which may aid in identifying critical pathways and mechanisms associated with the pathogenesis of gallbladder diseases.
Authors: Laetitia Finzi; Véronique Barbu; Pierre-Regis Burgel; Martine Mergey; Kimberly S Kirkwood; Elizabeth C Wick; Jean-Yves Scoazec; Frédérique Peschaud; François Paye; Jay A Nadel; Chantal Housset Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307
Authors: Anil K Chaturvedi; Troy J Kemp; Ruth M Pfeiffer; Angelique Biancotto; Marcus Williams; Stella Munuo; Mark P Purdue; Ann W Hsing; Ligia Pinto; J Philip McCoy; Allan Hildesheim Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-29 Impact factor: 4.254
Authors: Enju Liu; Lori C Sakoda; Yu-Tang Gao; Asif Rashid; Ming-Chang Shen; Bing-Sheng Wang; Jie Deng; Tian-Quan Han; Bai-He Zhang; Joseph F Fraumeni; Ann W Hsing Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-05 Impact factor: 4.254
Authors: A W Hsing; Y-T Gao; T-Q Han; A Rashid; L C Sakoda; B-S Wang; M-C Shen; B-H Zhang; S Niwa; J Chen; J F Fraumeni Journal: Br J Cancer Date: 2007-11-13 Impact factor: 7.640
Authors: Jill Koshiol; Felipe Castro; Troy J Kemp; Yu-Tang Gao; Juan Carlos Roa; Bingsheng Wang; Leticia Nogueira; Juan Carlos Araya; Ming-Chang Shen; Asif Rashid; Ann W Hsing; Allan Hildesheim; Catterina Ferreccio; Ruth M Pfeiffer; Ligia A Pinto Journal: Cytokine Date: 2016-05-09 Impact factor: 3.861
Authors: Michael B Cook; Matthew J Barnett; Cathryn H Bock; Amanda J Cross; Phyllis J Goodman; Gary E Goodman; Christopher A Haiman; Kay-Tee Khaw; Marjorie L McCullough; Christine C Newton; Marie-Christine Boutron-Ruault; Eiliv Lund; Martin Rutegård; Mark D Thornquist; Michael Spriggs; Carol Giffen; Neal D Freedman; Troy Kemp; Candyce H Kroenke; Loïc Le Marchand; Jin Young Park; Michael Simon; Lynne R Wilkens; Ligia Pinto; Allan Hildesheim; Peter T Campbell Journal: Gut Date: 2018-08-18 Impact factor: 23.059
Authors: Victoria L Brun; Amanda F Corbel; Ann W Hsing; Troy J Kemp; Alison L Van Dyke; Allan Hildesheim; Bin Zhu; Yu-Tang Gao; Ligia A Pinto; Jill Koshiol Journal: Sci Rep Date: 2021-06-28 Impact factor: 4.996
Authors: Martyna Pajewska-Szmyt; Elena Sinkiewicz-Darol; Renata Gadzała-Kopciuch Journal: Environ Sci Pollut Res Int Date: 2019-01-28 Impact factor: 4.223